Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.